Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OLYMPIA-4: Odronextamab vs Standard of Care in Relapsed/Refractory Aggressive B-cell Non-Hodgkin Lymphoma
2022-502783-21-00Phase 3Authorised
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Feb 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 23
01
Overview
Phase 3, randomised, open-label trial in B-cell non-Hodgkin lymphoma (B-NHL) comparing Odronextamab arm with Standard-of-care arm (2 arms). Primary endpoint: Event-free survival (EFS) as assessed by independent central review (ICR). Planned start Feb 2024; status: authorised.
02
Drugs
odronextamab
03
Conditions
B-cell non-Hodgkin lymphoma (B-NHL)
Beyond the preview
Go deeper on 2022-502783-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502783-21-00.